Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Empaveli Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.04.40

    Empaveli (pegcetacoplan) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.04.40 alerts

    Get alerted when Policy 05.04.40 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for Empaveli in adults with paroxysmal nocturnal hemoglobinuria (PNH) and adults or patients aged 12 years and older with complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyEmpaveli (pegcetacoplan) Coverage and Prior Authorization
    Policy CodePolicy 05.04.40
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionFor PNH, use Epysqli or Ultomiris before Empaveli unless inadequate response, intolerance, contraindication, or qualifying current Empaveli therapy applies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsMaximum initial PNH authorization
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum initial C3G or IC-MPGN authorization
    9 vials/28 daysEmpaveli quantity limit
    2Preferred PNH products
    ≥1 g/day or ≥1.0 g/gProteinuria or UPCR threshold
    3Listed provider billing codes

    Coverage Criteria

    Initial Therapy — PNH

    Covered for initial PNH therapy when all of the following are met:

    Initial PNH criteria

    • PNH diagnosis

      • The diagnosis of PNH is confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs).At least 5% PNH cells or at least 51% of GPI-AP-deficient polymorphonuclear cells.
    • Flow cytometry

      • Flow cytometry is used to demonstrate GPI-AP deficiency.
    • Clinical manifestations

      • The member has and exhibits clinical manifestations of PNH.Examples include LDH >1.5 ULN, thrombosis, renal dysfunction, pulmonary hypertension, or dysphagia.
    • No combination therapy

      • Empaveli will not be used in combination with another complement inhibitor for the treatment of PNH.

        Transition from eculizumab or ravulizumab to Empaveli is allowed.

    Initial Therapy — C3G or IC-MPGN

    Covered for initial C3G or IC-MPGN therapy when all of the following are met:

    Initial C3G or IC-MPGN criteria

    • Biopsy-confirmed diagnosis

      • The diagnosis of C3G or primary IC-MPGN is confirmed by kidney biopsy.

        For patients aged 12 years and older.

    • Proteinuria or UPCR

      • Proteinuria is at least 1 g/day.≥1 g/day

        Obtained within 3 months before initiation.

      • Baseline UPCR is at least 1.0 g/g.≥1.0 g/g

    Continuation Therapy — PNH

    Covered for continuation PNH therapy when all of the following are met:

    Continuation PNH criteria

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive response to therapy.Examples include improvement in hemoglobin levels or normalization of LDH levels.
    • Empaveli will not be used in combination with another complement inhibitor for the treatment of PNH.

      Transition from eculizumab or ravulizumab to Empaveli is allowed.

    Continuation Therapy — C3G or IC-MPGN

    Covered for continuation C3G or IC-MPGN therapy when all of the following are met:

    Continuation C3G or IC-MPGN criteria

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Therapeutic benefit

      • Proteinuria has decreased from baseline.
      • UPCR has decreased from baseline.

    Combination use is excluded: Empaveli must not be used with another complement inhibitor for the treatment of PNH, including Fabhalta, Piasky, Soliris, or Ultomiris. Transitioning from eculizumab or ravulizumab to Empaveli is permitted.

    Empaveli is contraindicated when the member is not currently vaccinated against certain encapsulated bacteria, unless the risk of delaying treatment outweighs the risk of developing a serious infection. It is also contraindicated in the presence of an unresolved serious infection caused by an encapsulated bacterium. The REMS program requires vaccination as recommended, generally at least 2 weeks before the first dose, unless delaying therapy presents the greater risk.

    Empaveli is considered not medically necessary when the member does not meet the applicable coverage criteria stated in this policy.

    Billing and Clinical Coding

    Provider services billing codesHCPCS
    J3490unclassified drugs
    J3590unclassified biologics
    C9399unclassified drugs or biologicals
    Provider Services Billing CodesHCPCS
    J3490unclassified drugs
    J3590unclassified biologics
    C9399unclassified drugs or biologicals
    PNH GPI-AP deficiency
    PNH cell thresholdAt least 5% PNH cells
    GPI-AP-deficient polymorphonuclear cellsAt least 51%
    Confirmation methodFlow cytometry demonstrates GPI-AP deficiency
    LDH clinical manifestation
    LDH threshold>1.5 times the upper limit of normal (ULN)
    Clinical roleQualifying clinical manifestation of PNH
    Other examples

    Provider Requirements and Authorization Actions

    Prior Authorization

    Plan Design and Initial Approval Review

    Requests must satisfy both the health plan’s Preferred Drug Plan Design and the applicable Criteria for Initial Approval when applicable.

    Prior Authorization

    PNH Preferred-Product Authorization

    Initial authorization for Empaveli for PNH is available only when the member meets one of the preferred-product exceptions or is already receiving Empaveli with a positive therapeutic outcome.

    • The member has an inadequate response, an intolerable adverse event, or a contraindication to Epysqli (eculizumab-aagh) or Ultomiris (ravulizumab).
    • The member is currently receiving Empaveli, excluding use obtained through samples or a manufacturer patient assistance program, and is experiencing a positive therapeutic outcome.
    Prior Authorization

    Initial Authorization Periods

    Clinical Background

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematologic disorder involving complement-mediated hemolysis. Clinical manifestations may include hemoglobinuria, fatigue, thrombosis, and bone marrow dysfunction. Empaveli is a targeted C3 complement inhibitor used in PNH to address complement-mediated disease manifestations.

    Definitions

    Complement 3 glomerulopathy (C3G)
    DefinitionA complement-mediated kidney disease diagnosis
    ConfirmationDiagnosis must be confirmed by kidney biopsy
    Age scopeAdults and pediatric patients aged 12 years and older
    Coverage contextEmpaveli is covered when applicable proteinuria or UPCR and background-treatment criteria are met
    Primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN)
    DefinitionPrimary immune-complex membranoproliferative glomerulonephritis
    Confirmation

    Initial Therapy Criteria

    Initial Therapy — PNH

    Initial PNH therapy requires the preferred-product exception and all applicable clinical criteria:

    Initial PNH authorization

    • Preferred-product exception

      • The member has had an inadequate response to Epysqli (eculizumab-aagh) or Ultomiris (ravulizumab).
      • The member has experienced an intolerable adverse event with Epysqli or Ultomiris.
      • The member has a contraindication to Epysqli or Ultomiris.
      • The member is currently receiving Empaveli and experiencing a positive therapeutic outcome.

        Empaveli obtained as samples or through a manufacturer's patient assistance program does not satisfy this exception.

    Continuation Therapy Criteria

    Continuation Therapy

    Authorization of 12 months may be granted for continuation therapy when the applicable indication-specific criteria are met:

    Continuation indications

    • PNH continuation

      • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
      • The member demonstrates a positive response to therapy.Examples include improvement in hemoglobin levels or normalization of LDH levels.
      • Empaveli will not be used in combination with another complement inhibitor for the treatment of PNH.

        Transition from eculizumab or ravulizumab to Empaveli is allowed.

    Preferred PNH Product Sequence

    StepPreferred PNH productRequirement before EmpaveliException
    1Epysqli (eculizumab-aagh) or Ultomiris (ravulizumab)Use one preferred product before the non-preferred product Empaveli.Inadequate response, intolerable adverse event, or contraindication to Epysqli or Ultomiris; or current Empaveli therapy with a positive therapeutic outcome. Empaveli obtained as samples or through a manufacturer patient assistance program does not qualify for the current-therapy exception.

    Quantity Limits

    Empaveli (pegcetacoplan)
    DrugEmpaveli (pegcetacoplan)
    Quantity limit9 vials
    Limit periodPer 28 days
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyEmpaveli (pegcetacoplan) Coverage and Prior Authorization
    Policy CodePolicy 05.04.40
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionFor PNH, use Epysqli or Ultomiris before Empaveli unless inadequate response, intolerance, contraindication, or qualifying current Empaveli therapy applies.
    SourceLink
    On This Page
    Coverage CriteriaBilling and Clinical CodingProvider Requirements and Authorization ActionsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaPreferred PNH Product SequenceQuantity Limits

    Obtained within 3 months before initiation.

  1. Background therapy

    • The member has received a stable dose of maximally tolerated RAS inhibitor and/or SGLT2 inhibitor therapy for at least 3 months before initiation.≥3 months

      RAS inhibitors include an ACE inhibitor or ARB.

    • The member has an intolerance or contraindication to RAS inhibitors or SGLT2 inhibitors.
  2. Thrombosis, renal dysfunction, pulmonary hypertension, or dysphagia
    Proteinuria
    Proteinuria thresholdAt least 1 g/day
    Applicable conditionsComplement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN)
    TimingMeasured within 3 months before initiation of the requested drug
    Baseline UPCR
    Baseline UPCR thresholdAt least 1.0 g/g
    Timing requirementObtained within 3 months before initiation
    Alternative to proteinuriaMay satisfy the criterion instead of proteinuria of at least 1 g/day
    RAS inhibitor or SGLT2 inhibitor therapy
    Required therapyRenin-angiotensin system (RAS) inhibitor therapy and/or SGLT2 inhibitor therapy
    Dose and durationStable dose at the maximally tolerated level for at least 3 months before initiation
    ExceptionsIntolerance or contraindication to RAS inhibitors or SGLT2 inhibitors
    RAS inhibitor examplesACE inhibitor or angiotensin receptor blocker (ARB)

    Initial authorization may be granted for up to six months for PNH and up to twelve months for C3G or primary IC-MPGN when all applicable initial-approval criteria are met.

    • PNH: maximum initial authorization period is 6 months.
    • C3G or primary IC-MPGN: maximum initial authorization period is 12 months.

    Unsupported block type: prior_auth

    Step Therapy

    Preferred PNH Product Step

    For PNH, members must use a preferred product before non-preferred Empaveli unless an applicable clinical exception is documented.

    • Preferred products are Epysqli (eculizumab-aagh) and Ultomiris (ravulizumab).
    • Empaveli may be authorized when the member has an inadequate response, an intolerable adverse event, or a contraindication to a preferred product, or when the member is already receiving Empaveli with a positive therapeutic outcome.
    Documentation Required

    PNH Documentation

    Submit flow cytometry results for initial PNH requests demonstrating deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs).

    • Documentation should confirm the PNH diagnosis through GPI-AP deficiency, such as at least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells.
    • Continuation requests require chart notes or other medical documentation supporting a positive clinical response.
    Documentation Required

    C3G or IC-MPGN Documentation

    For C3G or primary IC-MPGN, submit kidney biopsy confirmation and recent documentation of clinically significant proteinuria.

    • Initial requests require a kidney biopsy confirming C3G or primary IC-MPGN.
    • Provide a laboratory report or chart notes obtained within 3 months before initiation showing proteinuria ≥1 g/day or baseline UPCR ≥1.0 g/g.
    • Continuation requests require laboratory or chart documentation showing decreased proteinuria or UPCR from baseline.
    Prior Authorization

    Prescriber Specialty Requirement

    Empaveli must be prescribed by or in consultation with a nephrologist when requested for C3G or primary IC-MPGN.

    Denial Risk

    Failure to Meet Clinical Criteria

    Empaveli is not medically necessary when the member does not meet the applicable diagnostic, response, or safety criteria.

    • Initial PNH requests require confirmed GPI-AP deficiency and clinical manifestations of disease.
    • Initial C3G or primary IC-MPGN requests require kidney-biopsy confirmation, qualifying proteinuria or UPCR, and stable maximally tolerated RAS inhibitor and/or SGLT2 inhibitor therapy for at least 3 months, unless intolerance or contraindication is documented.
    • Continuation requests require clinical benefit and no unacceptable toxicity or disease progression.
    Denial Risk

    Concurrent Complement Inhibitor Use

    Do not use Empaveli in combination with another complement inhibitor for PNH. Transitioning from eculizumab or ravulizumab to Empaveli is permitted.

    • Prohibited concurrent examples include Fabhalta, Piasky, Soliris, and Ultomiris.
    • Document the transition when changing from eculizumab or ravulizumab to Empaveli.
    Step Therapy

    Preferred-Product Requirement

    Non-preferred Empaveli requires documented failure of, intolerance to, or contraindication to a preferred PNH product, unless the member is already receiving Empaveli with a positive therapeutic outcome.

    • Use Epysqli or Ultomiris before Empaveli when clinically appropriate.
    • Samples and manufacturer patient assistance program use do not qualify as current therapy for the existing-Empaveli exception.
    Denial Risk

    Vaccination and Serious-Infection Contraindication

    Before the first dose, the prescriber must ensure vaccination against specified encapsulated bacteria as recommended under the Empaveli REMS, generally at least 2 weeks before treatment.

    • Treatment may be started sooner only when the risks of delaying therapy outweigh the risks of developing a serious encapsulated-bacterial infection.
    • Empaveli is contraindicated in patients who are not currently vaccinated against the specified encapsulated bacteria unless that risk-benefit exception applies.
    • Empaveli is contraindicated in patients with an unresolved serious infection caused by encapsulated bacteria.
    Diagnosis must be confirmed by kidney biopsy
    Age scopeAdults and pediatric patients aged 12 years and older
    Coverage contextEmpaveli is covered when applicable proteinuria or UPCR and background-treatment criteria are met
    GPI-AP deficiency
    DefinitionDeficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs)
    Confirmation methodDemonstrated by flow cytometry
    Qualifying example 1At least 5% PNH cells
    Qualifying example 2At least 51% of GPI-AP-deficient polymorphonuclear cells
  3. PNH clinical criteria

    • The diagnosis of PNH is confirmed by detecting a deficiency of GPI-APs.At least 5% PNH cells or at least 51% of GPI-AP-deficient polymorphonuclear cells.
    • Flow cytometry is used to demonstrate GPI-AP deficiency.
    • The member has and exhibits clinical manifestations of PNH.Examples include LDH >1.5 ULN, thrombosis, renal dysfunction, pulmonary hypertension, or dysphagia.
    • Empaveli will not be used in combination with another complement inhibitor for the treatment of PNH.

      Transition from eculizumab or ravulizumab to Empaveli is allowed.

  4. Initial Therapy — C3G or IC-MPGN

    Initial C3G or IC-MPGN therapy requires all of the following:

    Initial C3G or IC-MPGN authorization

    • The member is aged 12 years or older.
    • The diagnosis of C3G or primary IC-MPGN is confirmed by kidney biopsy.
    • Proteinuria or UPCR

      • Proteinuria is at least 1 g/day.≥1 g/day

        Obtained within 3 months before initiation.

      • Baseline UPCR is at least 1.0 g/g.≥1.0 g/g

        Obtained within 3 months before initiation.

    • Background therapy

      • The member has received a stable dose of maximally tolerated RAS inhibitor and/or SGLT2 inhibitor therapy for at least 3 months before initiation.≥3 months

        RAS inhibitors include an ACE inhibitor or ARB.

      • The member has an intolerance or contraindication to RAS inhibitors or SGLT2 inhibitors.

    C3G or IC-MPGN continuation

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Therapeutic benefit

      • Proteinuria has decreased from baseline.
      • UPCR has decreased from baseline.